Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc., trading under the ticker symbol VOR, is at the forefront of cell and genome engineering, specifically focusing on hematopoietic stem cells (HSCs). Headquartered in Cambridge, Massachusetts, Vor Bio aims to revolutionize the treatment of hematological cancers, particularly acute myeloid leukemia (AML). The company’s pioneering platform involves engineering hematopoietic stem cells (eHSCs) to generate healthy and functional cells with beneficial modifications. These modifications protect the blood and bone marrow from the adverse effects of antigen-targeted therapies while leaving cancer cells vulnerable.
Key Products and Innovations:
- VOR33 (Trem-cel) - Vor Bio’s lead program, a CRISPR/Cas9 genome-edited allogeneic HSC transplant that lacks the CD33 protein. This product is designed to replace standard transplants for AML patients and potentially other blood cancers.
- VCAR33ALLO - A CD33-directed CAR-T cell therapy derived from healthy transplant donor cells. This approach aims to provide more potent and durable responses in the post-transplant setting without on-target toxicity.
Recent Achievements and Collaborations:
- Secured a non-exclusive worldwide license from Editas Medicine for ex-vivo Cas9 gene-edited HSC therapies.
- Partnership with Janssen for the preclinical development of CD33-deleted allografts and their synergistic effects with Janssen's CD33-targeted immunotherapy candidate.
Clinical Trials and Research:
- VBP101 Clinical Trial - Ongoing Phase 1/2a study of trem-cel in AML patients, showing promising engraftment results and hematologic protection.
- VCAR33ALLO Clinical Trial (VBP301) - A Phase 1/2 study involving CAR-T cell therapy derived from healthy transplant donors, showing initial successful dosing and manufacturing capabilities.
Financial Updates: In its latest quarterly report, Vor Bio announced positive financial outcomes, including an extended cash runway into the second half of 2025. The company is focused on executing its clinical trials and expanding its platform to include additional innovative therapies.
Future Outlook: Vor Bio is set to present at major scientific conferences, including the American Society of Hematology (ASH) Annual Meeting, where it will share significant preclinical and clinical data. The company is also looking forward to additional data releases from its clinical trials by year-end, which could further validate their treatment system for AML.
For more updates, visit www.vorbio.com.
Vor Bio reported financial results for Q3 2022, showing a cash position of $136.1 million, projected to fund operations until Q1 2024. R&D expenses increased to $16.9 million, driven by clinical trials and facility expansions. The net loss was $23.8 million. In-house clinical manufacturing is now operational, supporting the IND submission for VCAR33 in H1 2023. The company plans to present initial clinical data for VOR33 by the end of 2022 and has received ATMP status from EMA for VOR33 and VCAR33.
Vor Bio (Nasdaq: VOR) has announced its participation in several upcoming investor conferences. Key events include:
- Credit Suisse 31st Annual Healthcare Conference: Virtual presentation on November 8, 2022.
- Stifel 2022 Healthcare Conference: Fireside chat on November 16, 2022, at 10:20 am EST in New York, NY.
- Jefferies London Healthcare Conference: Fireside chat on November 17, 2022, at 3:15 pm GMT in London, UK.
Webcasts of these events will be available on Vor Bio's investor section.
Vor Bio (Nasdaq: VOR) has appointed Dr. Eyal C. Attar as Chief Medical Officer, bringing over 20 years of clinical experience, particularly in hematologic malignancies. The company anticipates important clinical trial data for VOR33 later this year, alongside an IND submission for VCAR33ALLO planned for early next year. Dr. Attar's expertise in AML and prior roles at Aprea Therapeutics and Agios Pharmaceuticals are expected to enhance Vor Bio's clinical development capabilities. An inducement equity award of 364,000 stock options was granted to Dr. Attar as part of his appointment.
Vor Bio (Nasdaq: VOR) presented promising preclinical data on its novel base editing platform for hematopoietic stem cell (HSC) engineering at the ESGCT Annual Congress in Edinburgh. Their research showcased the successful multiplex deletion of myeloid antigens CD33 and CLL-1, which maintained HSC function and exhibited long-term engraftment without genotoxic risks. This innovative approach is aimed at improving safety and efficacy for treating acute myeloid leukemia (AML), addressing significant challenges in current therapies.
Vor Bio has opened a new in-house clinical manufacturing facility in Cambridge, MA, to enhance the production of engineered hematopoietic stem cells (eHSCs) and CAR-T therapies targeting blood cancers. This facility aims to improve integration across teams, reduce manufacturing time and cost, and boost operational efficiency for ongoing clinical trials. The facility includes four cleanrooms and is designed to comply with Good Manufacturing Practice (cGMP) standards. The company plans to support the IND submission for VCAR33 by mid-2023.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced its participation in several investor conferences in September 2022.
The events include:
- Morgan Stanley 20th Annual Global Healthcare Conference: September 12, 2022, at 4:50 pm ET in New York, NY
- H.C. Wainwright 24th Annual Global Investment Conference: September 14, 2022, at 8:30 am ET in New York, NY
- Baird’s 2022 Global Healthcare Conference: September 14, 2022, at 10:50 am ET in New York, NY
- Jefferies Cell and Genetic Medicine Summit: September 30, 2022, in New York, NY
A live webcast of the Morgan Stanley chat will be available on vorbio.com.
Vor Bio (Nasdaq: VOR) announced its Q2 2022 financial results, reporting a net loss of $21.7 million, up from $18.4 million in Q2 2021. Cash reserves of $151.1 million will support operations into Q1 2024. The company is on track to share initial clinical data for its lead candidate VOR33 in Q4 2022, which aims to provide a treatment for acute myeloid leukemia (AML). The operational in-house manufacturing facility in Cambridge, MA is also expected to begin operations in Q4 2022, enhancing production capabilities for future therapies.
Vor Bio (Nasdaq: VOR) will participate in two upcoming investor conferences in August 2022. The first is the BTIG Biotechnology Conference 2022 where a pre-recorded fireside chat will be available starting August 8 at 9:00 AM ET. The second event is the 2022 Wedbush PacGrow Healthcare Conference, featuring a panel discussion titled A View to a Kill(er Cell) - Part 1 on August 10 at 1:10 PM ET. Live webcasts and archived replays will be accessible on their investor website, showcasing Vor Bio's commitment to advancing treatments for blood cancers.
Vor Bio (Nasdaq: VOR) announced a breakthrough in gene editing with the successful dual editing of CD33 and CLL-1 in human hematopoietic stem cells, targeting acute myeloid leukemia (AML). This pre-clinical data, presented at the European Hematology Association Congress, shows long-term persistence of modified cells with minimal translocation risk. The study indicates that the edited cells maintain function and offer protection against targeted immunotherapy, potentially increasing the efficacy of treatments for AML, which has low survival rates post-transplant.
Vor Bio (Nasdaq: VOR) will participate in several investor conferences in June 2022. Key events include the Jefferies Healthcare Conference on June 8 at 2:30 PM ET in New York, the Goldman Sachs Global Healthcare Conference from June 13-16 in California, and a Fireside Chat at the JMP Securities Life Sciences Conference on June 16 at 11:00 AM ET in New York. Additionally, Vor Bio will join Stifel’s 2022 Virtual Cell Therapy Summit on June 29-30. Live webcasts of these presentations will be available on their website.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
What is Vor Biopharma Inc. known for?
What are the main products of Vor Biopharma Inc.?
Where is Vor Biopharma Inc. located?
What recent achievements has Vor Biopharma Inc. made?
What clinical trials are currently being conducted by Vor Biopharma Inc.?
What is the potential impact of Vor Biopharma Inc.'s platform?
How can I stay updated on Vor Biopharma Inc.'s progress?
What financial updates were provided by Vor Biopharma Inc. recently?
What upcoming milestones is Vor Biopharma Inc. expecting?
What collaborations has Vor Biopharma Inc. entered into?
